Accessibility Menu
 
Defence Therapeutics logo

Defence Therapeutics

(OTC) DTCFF

Current Price$0.43
Market Cap$24.76M
Since IPO (2021)-83%
5 YearN/A
1 Year-57%
1 Month-3%

Defence Therapeutics Financials at a Glance

Market Cap

$24.76M

Revenue (TTM)

$0.00

Net Income (TTM)

$4.18M

EPS (TTM)

$-0.06

P/E Ratio

-7.47

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.43

Volume

500

Open

$0.43

Previous Close

$0.43

Daily Range

$0.43 - $0.43

52-Week Range

$0.31 - $1.00

DTCFF News

No articles available.

DTCFF: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Defence Therapeutics

Industry

Biotechnology

CEO

Sébastien Plouffe

Headquarters

Vancouver, BC V6C 3L6, CA

DTCFF Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

0%

Return on Capital

-16%

Return on Assets

-3%

Earnings Yield

-13.39%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$24.76M

Shares Outstanding

57.37M

Volume

500

Short Interest

0.00%

Avg. Volume

8.26K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$3.00M

EBITDA

$2.93M

Operating Cash Flow

$3.00M

Capital Expenditure

$0.00

Free Cash Flow

$3.00M

Cash & ST Invst.

$1.23M

Total Debt

$1.50M

Defence Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$9.27K

N/A

Gross Margin

0.00%

N/A

Market Cap

$24.76M

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

$1.52M

-88.9%

EBITDA

$1.40M

-106.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Net Cash

$539.92K

+53.2%

Accounts Receivable

$222.50K

+384.9%

Inventory

$0.00

N/A

Long Term Debt

$1.49M

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-3.17%

N/A

Return on Invested Capital

-15.74%

N/A

Free Cash Flow

$1.39M

-108.4%

Operating Cash Flow

$1.40M

-109.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MBXBFMicrobix Biosystems Inc.
$0.18-3.72%
PVCTProvectus Biopharmaceuticals, Inc.
$0.05-3.77%
FNCHFinch Therapeutics Group, Inc.
$12.00-6.18%
MMIRFMedMira Inc.
$0.05+239.10%

Trending Stocks

Symbol / CompanyPricePrice Chg
CMCSAComcast
$29.02+0.00%
INTCIntel
$43.87-0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.08-0.06%
TAT&T
$28.31+0.02%

Questions About DTCFF

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.